Related Experiment Videos
p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma
G Busatto1, Y H Shiao, A R Parenti
1Istituto di Anatomia Patologica, Università di Padova, Italy.
Molecular Pathology : MP
|August 26, 1998
Summary
p16/CDKN2 mutations are rare in esophageal squamous carcinoma. Alterations in the retinoblastoma susceptibility gene (Rb) appear crucial for tumor development, showing an inverse relationship with p16/CDKN2 expression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cell cycle regulation involves p16/CDKN2 and retinoblastoma susceptibility gene (Rb).
- An inverse relationship between p16/CDKN2 and Rb expression is known in many tumors.
- This relationship was previously undetermined in esophageal squamous carcinoma.
Purpose of the Study:
- Investigate p16/CDKN2 genetic alterations in esophageal squamous carcinoma.
- Analyze p16/CDKN2 and Rb protein (pRb) immunophenotypes in these tumors.
- Determine the relationship between p16/CDKN2 and pRb in tumor development.
Main Methods:
- Examined 20 esophageal squamous carcinomas for p16/CDKN2 mutations using PCR, SSCP, and DNA sequencing.
- Assessed p16/CDKN2 and pRb protein synthesis via immunohistochemistry in 19 tumor tissues.
- Analyzed genetic alterations and protein expression patterns.
Main Results:
- No p16/CDKN2 mutations were found in exons 1 and 2; rare changes occurred in exon 3.
- p16/CDKN2 and Rb expression was present in normal and neoplastic tissues.
- Fourteen tumors exhibited inverse p16/CDKN2 and Rb expression, with 8 showing increased p16/CDKN2 and decreased/absent pRb.
Conclusions:
- p16/CDKN2 mutations are infrequent in esophageal squamous carcinoma.
- Alterations in the Rb gene are implicated as a significant factor in tumor development.
- The study suggests a role for Rb gene alterations in the pathogenesis of these cancers.